deltatrials
Active Not Recruiting PHASE2 NCT02755272

A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

A Randomized Phase II Clinical Trial Assessing the Efficacy and Safety of MK-3475 (Pembrolizumab) in Combination With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

Sponsor: Fox Chase Cancer Center

Conditions Carcinoma Breast Stage IV
Interventions Carboplatin Gemcitabine Pembrolizumab
Updated 19 times since 2017 Last updated: Jul 2, 2025 Started: May 31, 2016 Primary completion: May 31, 2026 Completion: May 31, 2026

This PHASE2 trial investigates Carcinoma Breast Stage IV and is currently ongoing. Fox Chase Cancer Center leads this study, which shows 19 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

19 versions recorded

  1. Sep 2025 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Aug 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2024 — Aug 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Dec 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 14 earlier versions

  1. Jul 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  2. Dec 2022 — Jul 2023 [monthly]

    Recruiting PHASE2

  3. Dec 2021 — Dec 2022 [monthly]

    Recruiting PHASE2

  4. Sep 2021 — Dec 2021 [monthly]

    Recruiting PHASE2

  5. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  6. Jan 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

  7. Jun 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  8. Mar 2019 — Jun 2020 [monthly]

    Recruiting PHASE2

  9. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE2

  10. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE2

  11. Jun 2018 — Jan 2019 [monthly]

    Recruiting PHASE2

  12. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  13. Feb 2017 — Mar 2018 [monthly]

    Recruiting PHASE2

  14. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

May 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Fox Chase Cancer Center
  • University of Wisconsin, Madison
Data source: Fox Chase Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Durham, United States
  • • Indianapolis, United States
  • • Madison, United States
  • • Philadelphia, United States
  • • St Louis, United States
  • • The Bronx, United States